We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Gene Blocking Fails to Stop Tumor Growth

By Biotechdaily staff writers
Posted on 19 Jan 2005
Cancer researchers have found that blocking genes to prevent tumor growth is only temporarily successful, as cells that survive the treatment grow back in a manner that is often no longer regulated by the gene.

Investigators at the University of Pennsylvania School of Medicine (Philadelphia, USA; www.med.upenn.edu) worked with a mouse model to study the effect of blocking c-MYC regulation on mammary cancer. More...
C-Myc, a proto-oncogene located at 8q24, is a member of the Myc gene family that also includes the closely related N-Myc, L-Myc, P-Myc, R-Myc, S-Myc, and B-Myc genes. C-Myc spans 6-7 kb of genomic DNA, and codes for 439 amino acids. The C-Myc gene encodes a 66 kDa nuclear DNA-binding protein that regulates gene transcription and is responsible for growth control and cell cycle progression. The location of the C-Myc gene has been identified as one of the three most commonly amplified genomic regions in breast cancer, and C-Myc overexpression has been described in 70-100% of breast cancer tissues.

Previous research had suggested that preventing C-Myc expression would stop the growth of mammary cancers. However, results published in the December 2004 issue of Cancer Cell revealed that 50% of c-Myc-induced mammary cancers were able to grow in a mouse model lacking c-Myc expression. In addition, residual cancer cells remained from virtually all tumors that did regress, and these residual cells rapidly recovered their malignant properties following c-MYC reactivation or spontaneously recurred in a MYC-independent manner.

Senior author Dr. Lewis A. Chodosh, associate professor of cancer biology and medicine at the University of Pennsylvania School of Medicine, explained, "When physicians apply a selective pressure to a tumor by blocking an oncogenic pathway, cells escape. They find a back door and progress to a more aggressive state that becomes independent of that pathway.”




Related Links:
University of Pennsylvania School of Medicine

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.